company background image
YP1A logo

Immutep DB:YP1A Stock Report

Last Price

€2.24

Market Cap

€276.0m

7D

3.7%

1Y

50.3%

Updated

26 Mar, 2024

Data

Company Financials +

YP1A Stock Overview

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases.

YP1A fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Immutep Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immutep
Historical stock prices
Current Share PriceAU$2.24
52 Week HighAU$2.90
52 Week LowAU$1.35
Beta1.81
1 Month Change10.89%
3 Month Change9.80%
1 Year Change50.34%
3 Year Change-7.44%
5 Year Change15.46%
Change since IPO48.44%

Recent News & Updates

Recent updates

Shareholder Returns

YP1ADE BiotechsDE Market
7D3.7%2.1%1.9%
1Y50.3%37.0%7.3%

Return vs Industry: YP1A exceeded the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: YP1A exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is YP1A's price volatile compared to industry and market?
YP1A volatility
YP1A Average Weekly Movement9.9%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: YP1A has not had significant price volatility in the past 3 months.

Volatility Over Time: YP1A's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1987n/aMarc Voigthttps://www.immutep.com

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.

Immutep Limited Fundamentals Summary

How do Immutep's earnings and revenue compare to its market cap?
YP1A fundamental statistics
Market cap€275.99m
Earnings (TTM)-€24.42m
Revenue (TTM)€2.37m

116.4x

P/S Ratio

-11.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
YP1A income statement (TTM)
RevenueAU$3.93m
Cost of RevenueAU$37.72m
Gross Profit-AU$33.79m
Other ExpensesAU$6.71m
Earnings-AU$40.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.034
Gross Margin-859.57%
Net Profit Margin-1,030.32%
Debt/Equity Ratio0.8%

How did YP1A perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.